Invasive Strategies in Older Adults Undergoing Revascularization for NSTEMI and STEMI: Insights from Two Recent Meta-Analyses
Short summary is here.
👇👇👇
www.linkedin.com/pulse/invasi...
🥸2️⃣0️⃣ Early AVR for asymptomatic severe AS: fewer HF hospitalizations and strokes, similar mortality, and a strategy worth considering for improving patient outcomes.
🥸1️⃣9️⃣ The findings offer a framework for shared decision-making: reducing stroke and hospitalization vs. delaying AVR to avoid procedural risks in asymptomatic severe AS.
🥸1️⃣8️⃣ Limitations include lack of patient-level data, differences in AVR modalities (SAVR vs. TAVR), and variability in study populations, highlighting areas for future research.
🥸1️⃣7️⃣ Long-term follow-up is needed to assess reintervention rates due to valve durability, especially in younger patients, balancing early benefits with lifetime management.
🥸1️⃣6️⃣ Guideline changes may emerge as more data highlight reduced hospitalizations and stroke risks with early AVR, supporting timely intervention for severe AS.
🥸1️⃣5️⃣ Meta-analysis provides evidence for patient-centric benefits of early AVR, emphasizing quality of life rather than extending survival in asymptomatic severe AS.
🥸1️⃣4️⃣ Current findings challenge assumptions about “watchful waiting” for asymptomatic severe AS, favoring earlier treatment to reduce HF hospitalization and stroke risks.
🥸1️⃣3️⃣ Procedural stroke rates for modern TAVR platforms remain low (1-2%). Combined with stroke reductions in AVR arms, this supports early intervention's safety profile.
🥸1️⃣2️⃣ TAVR trials showed shorter delays to AVR in CS arms (e.g., 32 days in EARLY TAVR), likely minimizing exposure to high-risk symptomatic periods and impacting mortality outcomes.
🥸1️⃣1️⃣ Early AVR enables stable intervention, avoiding risks associated with emergency procedures during acute decompensation. This proactive strategy is key for asymptomatic patients.
🥸🔟 Differences in survival benefit likely relate to delays in AVR in CS groups, particularly in surgical trials where time from symptoms to AVR exceeded 4 months.
🥸9️⃣ Subgroup analyses showed SAVR trials (RECOVERY, AVATAR) suggested a survival benefit over CS, unlike TAVR trials (EARLY TAVR, EVoLVeD), reflecting different populations and approaches.
🥸8️⃣ Mortality findings showed moderate heterogeneity (I²: 61% for all-cause mortality, 50% for cardiovascular mortality), highlighting variations across trials and populations.
🥸7️⃣ Stroke reduction may stem from AVR’s role in reducing thromboembolic risk, subclinical atrial fibrillation, or valve-associated events—common in untreated severe AS.
🥸6️⃣ Hospitalization reductions with early AVR likely reflect relief of pressure overload on the left ventricle, preventing progression to symptomatic or decompensated states.
🥸5️⃣ This meta-analysis pooled data from 4 RCTs, including 1,427 patients (719 early AVR, 708 CS) with a follow-up of 4.1 years on average. A robust dataset supports its conclusions.
🥸4️⃣ Cardiovascular mortality also showed no significant difference (5.1% vs. 8.3%, HR: 0.67; 95% CI: 0.35-1.29). Lack of mortality benefit may relate to patient selection, timing, and competing risks in older populations.
🥸3️⃣ No significant difference in all-cause mortality between early AVR and CS (9.7% vs. 13.7%, HR: 0.68; 95% CI: 0.40-1.17). Mortality outcomes suggest AVR doesn’t necessarily extend life but improves other critical health outcomes.
🥸2️⃣ Stroke risk was also lower with early AVR: 4.5% vs. 7.2% (HR: 0.62; 95% CI: 0.40-0.97). The findings underscore how AVR may mitigate valve-related thromboembolic risks and structural cardiac damage over time.
🥸1️⃣ Early aortic valve replacement (AVR) significantly reduced unplanned cardiovascular or HF hospitalizations vs. clinical surveillance (CS): 14.6% vs. 31.9% (HR: 0.40; 95% CI: 0.30-0.53). This highlights the impact of proactive intervention in asymptomatic severe aortic stenosis (AS).
Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis: @jaccjournals.bsky.social
🥸Early TAVR led to less unplanned CV or HF hospitalization and stroke: @PhilGenereuxMD
😱 Summary
👇👇👇
🥸Two meta-analyses for older adults undergoing revascularization:
😱NSTEMI: ahajournals.org/doi/epub/10....
😱 STEMI: agsjournals.onlinelibrary.wiley.com/doi/epdf/10....
🥸We had a great journal club at American Geriatric Society with Dr Michael Nana on revacdularization in older adults
🥸2️⃣0️⃣ Results support clopidogrel as an effective and safer alternative to aspirin for long-term secondary prevention in PCI patients.
🥸1️⃣9️⃣ Sensitivity analyses confirmed findings with balanced baseline characteristics and consistent treatment effects.
🥸1️⃣8️⃣ Clopidogrel reduced thrombotic and bleeding risks without significant interaction by HBR or PCI complexity, reinforcing its consistency.
🥸1️⃣7️⃣ No significant differences in all-cause mortality between clopidogrel and aspirin were observed in any subgroup.
🥸1️⃣6️⃣ Subgroup analyses revealed numerical thrombotic benefits of clopidogrel in complex PCI and HBR groups, despite limited power.
